spironolactone has been researched along with Muscular Diseases in 7 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Muscular Diseases: Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chadwick, JA | 1 |
| Hauck, JS | 1 |
| Lowe, J | 1 |
| Shaw, JJ | 1 |
| Guttridge, DC | 1 |
| Gomez-Sanchez, CE | 1 |
| Gomez-Sanchez, EP | 1 |
| Rafael-Fortney, JA | 1 |
| Kinoshita, H | 1 |
| Okabayashi, M | 1 |
| Kaneko, M | 1 |
| Yasuda, M | 1 |
| Abe, K | 1 |
| Machida, A | 1 |
| Ohkubo, T | 1 |
| Kamata, T | 1 |
| Yakushiji, F | 1 |
| PEARSON, CM | 1 |
| Freedman, DB | 1 |
| Housley, D | 1 |
| Suzuki, A | 1 |
| Yoshida, M | 1 |
| Miura, Y | 1 |
| Oiso, Y | 1 |
| France, R | 1 |
| Stone, WJ | 1 |
| Michelakis, AM | 1 |
| Island, DP | 1 |
| Merrill, JM | 1 |
| Tolleson, WJ | 1 |
| Sambrook, MA | 1 |
| Heron, JR | 1 |
| Aber, GM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Open Label Trial of Spironolactone Versus Prednisolone in Corticosteroid-naïve Boys With DMD[NCT03777319] | Phase 1 | 2 participants (Actual) | Interventional | 2018-12-05 | Terminated (stopped due to Inability to recruit participants.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The determination of whether spironolactone has similar efficacy to glucocorticoids in improving muscle strength in steroid naïve DMD patients. This will be determined by measuring the time to complete a 100 meter timed test (100M). (NCT03777319)
Timeframe: 6 months
| Intervention | sec (Number) |
|---|---|
| Spironolactone | -0.6 |
| Prednisolone | -5.3 |
Secondary outcome measures will be Dynamometry score, which is a summation of maximum voluntary isometric contraction test values for knee flexion, knee extension, elbow flexion, and elbow extension (NCT03777319)
Timeframe: 6 months
| Intervention | kg (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elbow Flexion (Right)-Baseline | Elbow Flexion (Left)-Baseline | Elbow Extension (Right)-Baseline | Elbow Extension (Left)-Baseline | Knee Flexion (Right)-Baseline | Knee Flexion (Left)-Baseline | Knee Extension (Right)-Baseline | Knee Extension (Left)-Baseline | Elbow Flexion (Right)-Month 6 | Elbow Flexion (Left)-Month 6 | Elbow Extension (Right)-Month 6 | Elbow Extension (Left)-Month 6 | Knee Flexion (Right)-Month 6 | Knee Flexion (Left)-Month 6 | Knee Extension (Right)-Month 6 | Knee Extension (Left)-Month 6 | |
| Prednisolone | 3.6 | 4.1 | 5.3 | 4.1 | 3.3 | 3.4 | 4.8 | 5.2 | 2.9 | 3.4 | 4.3 | 3.8 | 4.1 | 3.9 | 6 | 5.1 |
| Spironolactone | 0 | 0 | 0 | 0 | 4.1 | 2.8 | 3.8 | 5.9 | 3.1 | 3.5 | 2.4 | 2.5 | 4.3 | 4.1 | 7.2 | 8.3 |
Electrolytes (Sodium, Potassium, Cloride and Carbon dioxide, mmol/L) will be measured on a monthly basis following initiation of either spironolactone or prednisolone. (NCT03777319)
Timeframe: 6 months
| Intervention | mmol/L (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sodium-Baseline | Sodium-Month 1 | Sodium-Month 2 | Sodium-Month 3 | Sodium-Month 4 | Sodium-Month 5 | Sodium-Month 6 | Potassium-Baseline | Potassium-Month 1 | Potassium-Month 2 | Potassium-Month 3 | Potassium-Month 4 | Potassium-Month 5 | Potassium-Month 6 | Chloride-Baseline | Chloride-Month 1 | Chloride-Month 2 | Chloride-Month 3 | Chloride-Month 4 | Chloride-Month 5 | Chloride-Month 6 | CO2-Baseline | CO2-Month 1 | CO2-Month 2 | CO2-Month 3 | CO2-Month 4 | CO2-Month 5 | CO2-Month 6 | |
| Prednisolone | 140 | 140 | 139 | 141 | 139 | 139 | 143 | 3.8 | 4 | 4.5 | 3.9 | 4.6 | 4.2 | 3.9 | 105 | 105 | 104 | 105 | 105 | 106 | 105 | 22 | 24 | 24 | 24 | 25 | 26 | 26 |
| Spironolactone | 142 | 142 | 141 | 142 | 139 | 139 | 140 | 4.5 | 4.7 | 4.2 | 4.1 | 4.5 | 4.5 | 4.3 | 103 | 109 | 107 | 103 | 103 | 103 | 101 | 29 | 22 | 25 | 27 | 28 | 28 | 26 |
7 other studies available for spironolactone and Muscular Diseases
| Article | Year |
|---|---|
Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target.
Topics: Aldosterone; Animals; Cell Line; Humans; Lisinopril; Mice; Muscle Fibers, Skeletal; Muscle Proteins; | 2015 |
Shakuyaku-kanzo-to induces pseudoaldosteronism characterized by hypokalemia, rhabdomyolysis, metabolic alkalosis with respiratory compensation, and increased urinary cortisol levels.
Topics: Aged; Alkalosis; Drug Combinations; Drugs, Chinese Herbal; Electrocardiography; Female; Glycyrrhiza; | 2009 |
THE PERIODIC PARALYSES: DIFFERENTIAL FEATURES AND PATHOLOGICAL OBSERVATIONS IN PERMANENT MYOPATHIC WEAKNESS.
Topics: Acetazolamide; Drug Therapy; Epinephrine; Humans; Hydrochlorothiazide; Hydrocortisone; Hyperkalemia; | 1964 |
Gitelman's syndrome presenting as intolerance to statin therapy.
Topics: Adult; Amiloride; Cholesterol; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutar | 2005 |
Gitelman's syndrome with silent thyroiditis.
Topics: Adult; Calcium; Female; Humans; Hypokalemia; Kidney Diseases; Magnesium; Muscular Diseases; Spironol | 2006 |
Renal potassium-wasting of unknown cause in a clinical setting of chronic potassium depletion: report of a case.
Topics: Aldosterone; Biopsy; Humans; Kidney; Kidney Tubules, Proximal; Magnesium; Male; Middle Aged; Muscula | 1973 |
Myopathy in association with primary hyperaldosteronism.
Topics: Electromyography; Humans; Hyperaldosteronism; Male; Middle Aged; Muscular Diseases; Potassium; Sodiu | 1972 |